NO20090738L - Tilveiebringelse av EP2 agonister, fremgangsmate for fremstilling derav, farmasoytiske sammensetninger inneholdende disse forbindelser og fremgangsmater for anvendelse av forbindelsene og sammensetningene for a senke intraokkulaert trykk og behandle glaukom - Google Patents

Tilveiebringelse av EP2 agonister, fremgangsmate for fremstilling derav, farmasoytiske sammensetninger inneholdende disse forbindelser og fremgangsmater for anvendelse av forbindelsene og sammensetningene for a senke intraokkulaert trykk og behandle glaukom

Info

Publication number
NO20090738L
NO20090738L NO20090738A NO20090738A NO20090738L NO 20090738 L NO20090738 L NO 20090738L NO 20090738 A NO20090738 A NO 20090738A NO 20090738 A NO20090738 A NO 20090738A NO 20090738 L NO20090738 L NO 20090738L
Authority
NO
Norway
Prior art keywords
compounds
methods
agonists
preparation
intraocular pressure
Prior art date
Application number
NO20090738A
Other languages
English (en)
Norwegian (no)
Inventor
Ganesh Prasanna
Charles Floyd Bosworth
Jennifer Anne Fontaine
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20090738L publication Critical patent/NO20090738L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20090738A 2006-07-28 2009-02-16 Tilveiebringelse av EP2 agonister, fremgangsmate for fremstilling derav, farmasoytiske sammensetninger inneholdende disse forbindelser og fremgangsmater for anvendelse av forbindelsene og sammensetningene for a senke intraokkulaert trykk og behandle glaukom NO20090738L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83390706P 2006-07-28 2006-07-28
US94192307P 2007-06-04 2007-06-04
PCT/IB2007/002044 WO2008015517A2 (en) 2006-07-28 2007-07-16 Ep2 agonists

Publications (1)

Publication Number Publication Date
NO20090738L true NO20090738L (no) 2009-04-27

Family

ID=38896126

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090738A NO20090738L (no) 2006-07-28 2009-02-16 Tilveiebringelse av EP2 agonister, fremgangsmate for fremstilling derav, farmasoytiske sammensetninger inneholdende disse forbindelser og fremgangsmater for anvendelse av forbindelsene og sammensetningene for a senke intraokkulaert trykk og behandle glaukom

Country Status (26)

Country Link
US (2) US7622475B2 (ja)
EP (1) EP2059507B1 (ja)
JP (1) JP4583500B2 (ja)
KR (1) KR101088942B1 (ja)
AP (1) AP2009004754A0 (ja)
AR (1) AR062122A1 (ja)
AU (1) AU2007280130B2 (ja)
BR (1) BRPI0714683A2 (ja)
CA (1) CA2659184C (ja)
CL (1) CL2007002207A1 (ja)
CR (1) CR10554A (ja)
EA (1) EA200970067A1 (ja)
EC (1) ECSP099071A (ja)
GT (1) GT200700064A (ja)
HK (1) HK1133876A1 (ja)
IL (1) IL196355A0 (ja)
MA (1) MA30604B1 (ja)
MX (1) MX2009001062A (ja)
NO (1) NO20090738L (ja)
NZ (1) NZ573964A (ja)
PE (1) PE20080408A1 (ja)
RS (1) RS20090002A (ja)
TN (1) TN2009000028A1 (ja)
TW (1) TWI372757B (ja)
UY (1) UY30511A1 (ja)
WO (1) WO2008015517A2 (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648097B2 (en) * 2008-03-12 2014-02-11 Ube Industries, Ltd. Pyridylaminoacetic acid compound
PL2415763T3 (pl) 2009-03-30 2016-05-31 Ube Industries Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 N-置換ヘテロアリール化合物
AU2010293410A1 (en) * 2009-09-11 2012-05-03 Ube Industries, Ltd. Substituted carbonyl compounds
KR20120068902A (ko) * 2009-09-11 2012-06-27 우베 고산 가부시키가이샤 아닐린 화합물
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
CN102666490A (zh) * 2009-12-25 2012-09-12 宇部兴产株式会社 氨基吡啶化合物
RU2013111281A (ru) * 2010-08-17 2014-09-27 Аллерган, Инк. Агонисты ер2 или ер4 для лечения помутнения роговицы
EA026702B1 (ru) 2011-09-16 2017-05-31 Санофи Производные анилина, их получение и терапевтическое применение
WO2013109991A1 (en) * 2012-01-20 2013-07-25 Acucela Inc. Substituted heterocyclic compounds for disease treatment
CA2867527A1 (en) 2012-05-03 2013-11-07 Takeda Gmbh Novel ep2 receptor agonists
US9339496B2 (en) 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
TW201527282A (zh) * 2013-03-28 2015-07-16 Ube Industries 取代聯芳基化合物
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び/又は予防のための医薬組成物
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
RU2749952C2 (ru) * 2015-07-01 2021-06-21 Сантэн Фармасьютикал Ко., Лтд. Депо-препарат, содержащий сложный эфир лимонной кислоты

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1000619A3 (en) 1998-06-23 2002-07-24 Pfizer Products Inc. Method for treating glaucoma
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
US20020161026A1 (en) 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
NZ532209A (en) 2001-11-30 2007-05-31 Pfizer Prod Inc Controlled release microparticle pharmaceutical composition for the sustained release of an EP2 receptor selective agonist for treating bone injury or bone defect
CA2473984A1 (en) * 2002-01-31 2003-08-07 Pfizer Products Inc. Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid
AU2004216898A1 (en) 2003-03-04 2004-09-16 Pfizer Products Inc. Use of EP2 selective receptor agonists in medical treatment
US20050203086A1 (en) 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma

Also Published As

Publication number Publication date
EA200970067A1 (ru) 2009-08-28
AP2009004754A0 (en) 2009-02-28
UY30511A1 (es) 2008-02-29
HK1133876A1 (en) 2010-04-09
KR20090023507A (ko) 2009-03-04
MX2009001062A (es) 2009-02-06
EP2059507B1 (en) 2013-03-20
US7622475B2 (en) 2009-11-24
AU2007280130A1 (en) 2008-02-07
WO2008015517A3 (en) 2008-06-12
WO2008015517A2 (en) 2008-02-07
CL2007002207A1 (es) 2008-02-01
TN2009000028A1 (fr) 2010-08-19
US20100105905A1 (en) 2010-04-29
CR10554A (es) 2009-02-10
CA2659184A1 (en) 2008-02-07
NZ573964A (en) 2010-11-26
EP2059507A2 (en) 2009-05-20
PE20080408A1 (es) 2008-04-28
AU2007280130B2 (en) 2011-09-22
TW200817360A (en) 2008-04-16
MA30604B1 (fr) 2009-07-01
CA2659184C (en) 2012-02-21
RS20090002A (en) 2010-06-30
US20080045545A1 (en) 2008-02-21
IL196355A0 (en) 2009-09-22
GT200700064A (es) 2009-06-18
KR101088942B1 (ko) 2011-12-01
TWI372757B (en) 2012-09-21
BRPI0714683A2 (pt) 2013-03-26
AR062122A1 (es) 2008-10-15
JP2009544751A (ja) 2009-12-17
JP4583500B2 (ja) 2010-11-17
ECSP099071A (es) 2009-02-27

Similar Documents

Publication Publication Date Title
NO20090738L (no) Tilveiebringelse av EP2 agonister, fremgangsmate for fremstilling derav, farmasoytiske sammensetninger inneholdende disse forbindelser og fremgangsmater for anvendelse av forbindelsene og sammensetningene for a senke intraokkulaert trykk og behandle glaukom
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
NO20090628L (no) Pyridizinon derivativater
NO20092138L (no) Forbindelser og sammensetninger som proteinkinase inhibitorer
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
NO20084850L (no) MGLUR5 modulatorer I
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
WO2008051942A3 (en) Farnesoid x receptor agonists
NO20093009L (no) Kondensert ring heterocykel kinase modulatorer
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
WO2008131000A3 (en) 7-substituted indole mcl-1 inhibitors
WO2008017932A3 (en) Heterocycles useful as inhibitors of carbonic anhydrase
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
EP1962838A4 (en) Farnesoid X RECEPTOR AGONISTS
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
NI200900052A (es) Heterocíclicos derivados de los inhibidores de metaloproteasa
NO20064344L (no) Caspaseinhibitorer og anvendelser derav
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
GB2466912A (en) Compositions and methods for treating lysosomal disorders
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application